Key result
The pyrazolopyridine derivatives 3a and 3c inhibited collagen-induced platelet aggregation with IC50 values of 61 μM and 68 μM, respectively, demonstrating nearly 5-fold greater potency than aspirin (IC50 300 μM).
New carbohydrazide derivatives (3a and 3c) demonstrated potent in vitro antiplatelet activity and favorable theoretical pharmacokinetic profiles, serving as prototypes for novel antithrombotic agents.
These derivatives merit preclinical testing as antiplatelet leads; leaves open any clinical antithrombotic role.
AIM: Platelets plays a central role in hemostatic processes and consequently are similarly involved in pathological processes, such as arterial thrombosis and atherosclerosis. Herein we described the synthesis, antiplatelet profile and structure-activity relationship (SAR) of a new series of N'-substitutedphenylmethylene-1H-pyrazolo[3,4-b]pyridine-carbohydrazide derivatives (3a-3k). METHODS: These compounds were synthesized in good yield and tested in platelet aggregation assays using collagen, ADP and arachidonic acid as agonists. We also performed a SAR studies using SPARTAN' 08 program, in silico ADMET screening and the Lipinski " rule of five " using Osiris Property Explorer and molinspiration on-line programs. RESULTS: Interestingly, the new compounds were active against collagen and arachidonic acid (AA) with the two most actives compounds (3a and 3c - IC(50)=61 microM and 68 microM respectively) almost 5-fold more potent than aspirin (IC(50)=300 microM). These derivatives showed low theoretical toxicity risks in in silico ADMET screening and fulfilled the Lipinski rule of five, suggesting good oral biodisponibility. CONCLUSION: This work showed carbohydrazide group as potential for designing new antiplatelets. On that purpose, 3a and 3c may act as prototypes to generate more efficient and safe molecules for treating thrombotic diseases.
No takes yet. Share an insight, caveat, or question.
Geraldo et al. (2010) studied Thrombotic diseases (preclinical). Pyrazolopyridine derivatives (3a and 3c) vs. Aspirin was evaluated on Inhibition of collagen-induced platelet aggregation (IC50 in μM). The pyrazolopyridine derivatives 3a and 3c inhibited collagen-induced platelet aggregation with IC50 values of 61 μM and 68 μM, respectively, demonstrating nearly 5-fold greater potency than aspirin (IC50 300 μM).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: